At a glance
- Originator Daiichi Pharmaceutical
- Class Antineoplastics; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Sep 2001 New profile
- 20 Sep 2001 Preclinical development for Cancer in Japan (Unknown route)